Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening disease. We investigated associations between markers of disease severity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat. We also present safety and efficacy from the final data cutoff of CHEST-2, where most patients had received riociguat for at least 2 years.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Respir Med

Title: The Lancet. Respiratory medicine

Publisher: Elsevier BV

ISSN (Electronic): 2213-2619

ISSN (Print): 2213-2600

Publication date (Electronic): May 2016

Volume: 4

Issue: 5

Affiliations

[1 ] Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France; INSERM Unité 999, l'Hopital Bicêtre, Le Kremlin-Bicêtre, France. Electronic address: gerald.simonneau@abc.ap-hop-paris.fr.

[2 ] Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, Italy.

[3 ] University of Giessen and Marburg Lung Centre (UGMLC), Giessen, Germany; German Centre of Lung Research (DZL), Giessen, Germany; Department of Medicine, Imperial College London, London, UK.

[4 ] University of Giessen and Marburg Lung Centre (UGMLC), Giessen, Germany; German Centre of Lung Research (DZL), Giessen, Germany.

[5 ] Clinical Department of Cardiology and Angiology of the First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic.

[6 ] Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.

[7 ] Kerckhoff Heart and Lung Centre, Bad Nauheim, Germany.

[8 ] National Heart Institute, Cardiopulmonary Department, Mexico City, Mexico.

[9 ] Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Beijing, China; Department of Respiratory Medicine, Capital Medical University, Beijing, China; Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, China.

[10 ] Global Clinical Development, Bayer Pharma AG, Barcelona, Spain.

[11 ] Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany.

[12 ] Global Clinical Development, Bayer Pharma AG, Berlin, Germany.

[13 ] German Centre of Lung Research (DZL), Giessen, Germany; Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany.

Article

Publisher Item ID: S2213-2600(16)30022-4

DOI: 10.1016/S2213-2600(16)30022-4

PubMed ID: 27067478

SO-VID: 91ee050c-907f-470a-a500-9a59ac148f59

History

Data availability:

Comments

Comment on this article

scite_

Cited by 46

See all cited by

- Version 1